1 Adverse Clinical Events
Short-Term Controlled Trials
In the Pravastatin
sodium placebo-controlled clinical trials database of 1313 patients (age range 20 to 76 years, 32.4% women, 93.5% Caucasians, 5% Blacks, 0.9% Hispanics, 0.4% Asians, 0.2% Others) with a median treatment duration of 14 weeks, 3.3% of patients on Pravastatin sodium and 1.2% patients on placebo discontinued due to adverse events regardless of causality.